Cancer Treatment of Tomorrow, Today
February 6, 2024
Moores Cancer Center continues to bring state-of-the-art cancer treatments from the bench to the bedside.
Your search for “Monoclonal Antibodies” returned 56 results
$150 Million Gift Takes Stem Cell Research to New Heights
September 6, 2022
Noted businessman and philanthropist T. Denny Sanford has committed $150 million in new funding to expand and, in some ways, quite literally launch stem cell research and regenerative medicine at University of California San Diego into new spaces and endeavors.
Neurosurgeon: My Patients Show Me Real Heroism and Resilience
March 11, 2024
UC San Diego Health provides the most advanced neurological cancer care by combining leading-edge surgical techniques and the latest technology.
Three UC San Diego Professors Named Recipients of 2018 Breakthrough Prize
December 3, 2017
Two full-time University of California San Diego faculty members — Don Cleveland, who studies fundamental cellular mechanisms in the search for new treatments for diseases like amyotrophic lateral sclerosis (ALS), and James McKernan, a mathematician who investigates algebraic geometry and multivariate polynomials — are recipients of the 2018 Breakthrough Prize,…
Cancer Isn’t Taking a Timeout for COVID-19; Neither are Clinical Trials
July 23, 2020
…trial uses a bispecific monoclonal antibody—an artificial protein that binds to two different types of antigen—to engage multiple T-cell targets simultaneously with the intent of making combination immunotherapies more effective. “UC San Diego Health stepped up and made sure I got the next best thing,” said Thurman. “It’s literally a…
Top UC San Diego Researchers Win ‘Oscars of Science’
December 7, 2017
…development of two major monoclonal antibody drugs: Bevacizumab (marketed as Avastin), which is used to treat multiple forms of cancer, including breast, brain and colorectal, and ranibizumab (marketed as Lucentis), which treats wet age-related macular degeneration, a leading cause of blindness in the elderly. For more information on the Breakthrough…
